Elacestrant
- Generic Name
- Elacestrant
- Brand Names
- Orserdu
- Drug Type
- Small Molecule
- Chemical Formula
- C30H38N2O2
- CAS Number
- 722533-56-4
- Unique Ingredient Identifier
- FM6A2627A8
- Background
Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its abili...
- Indication
Elacestrant is indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 220
- Registration Number
- NCT05512364
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Pole Hospitalier Jolimont - Hopital Jolimont, Haine-Saint-Paul, Belgium
🇧🇪CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT05386108
- Locations
- 🇫🇷
Centre Léon Bérard - Département Oncologie Médicale, Lyon, France
🇩🇪Universitätsklinikum Leipzig, Leipzig, Germany
🇺🇸Providence Medical Foundation, Fullerton, California, United States
Elacestrant in Preoperative Setting, a Window of Opportunity Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 23
- Registration Number
- NCT04797728
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital General de Catalunya, Sant Cugat Del Vallès, Barcelona, Spain
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04791384
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT03778931
- Locations
- 🇺🇸
Dayton Oncology & Hematology, Kettering, Ohio, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02338349
- Locations
- 🇺🇸
Radius Pharmaceuticals, Inc., Waltham, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.